IBO Impact BioMedical Aggregate Debt Obligations

Impact BioMedical Inc (IBO) focuses on the commercialization of biomedical patents in the fight against viruses and cancer through B2B licensing. This price chart illustrates the company's performance, where the separate_debt metric stands at 0.00. The business relies on intellectual property management in the US, generating revenue from royalties on specialized supplements and disinfectants.

Company Aggregate Debts: Impact BioMedical Inc (IBO) for 09/17/2024 - 10/28/2026

Impact BioMedical Inc - analytical breakdowns and key metrics (IBO)

- price and consensus price forecast:
Stock Price Impact BioMedical, Inc.|IBO - Price Target Chart
- market capitalization data:
Market Value Impact BioMedical|IBO - Total Company Value
- book capitalization data:
Accounting Value per Share Impact BioMedical|IBO - Book Capitalization|Market Capitalization to Book Value Ratio impactbiomedinc.com|IBO - Cumulative Company Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Impact BioMedical Inc|IBO - Long-Term Debt to Equity|Current Liabilities to Capital impactbiomedinc.com|IBO - Company Total Debt|Debt to Book Capital Impact BioMedical
Comprehensive company analysis:IBO Impact BioMedical, Inc.

For Impact BioMedical Inc (IBO), which monetizes biodefense patents, the total debt trajectory serves as an indicator of the balance between financial autonomy and expansion rates. This metric aggregates all of the company's borrowed obligations, allowing investors to assess the level of credit burden relative to stable royalty streams, where reducing debt minimizes default risks but may limit the speed of capturing new market niches.

Main competitors

Company Aggregate Debts HLN (Haleon Corp)|Company Debts Kenvue Inc.|veronapharma.com - Aggregate Debt Obligations|MENS: Company Debts|LGND - Company Total Debt|AMRX: Company Aggregate Debts|Company Aggregate Debts Perrigo Corp|ALVO - Company Total Debt|Aggregate Debt Obligations LQDA|Galapagos - Company Debts|Company Cumulative Debt ANI Pharmaceuticals Inc ANIP|Company Total Debt MannKind Corp. (MNKD)|Company Cumulative Indebtedness Amphastar Corp AMPH|Company Aggregate Debts Pacira BioSciences (PCRX)|SPRY - Aggregate Debt Obligations|Company Aggregate Debts TBPH|AQST (Aquestive Therapeutics Inc) - Company Cumulative Debt|SCPH - Company Debts|Aggregate Debt Obligations Tectonic|TNXP (Tonix Pharmaceuticals) - Company Aggregate Debts|Company Total Debt Obligations SXTC (sxtchina.com)|Eupraxia Pharmaceuticals Inc. - Company Debts|BioHarvest Sciences, Inc. - Company Total Debt|Company Debts Invizyne Technologies, Inc.|ORMP - Company Aggregate Indebtedness|ENTX: Company Aggregate Debts|ipatherapeutics.com (HYFT) - Company Aggregate Debts|Company Aggregate Debts ABVC|Company Total Debt Cumberland Pharmaceuticals Inc (CPIX)|Company Total Debt Quantum BioPharma Limited|Company Cumulative Indebtedness FibroGen Corporation FGEN|Company Total Debt Telomir Pharmaceuticals|Aggregate Debt Obligations Rani Therapeutics Holdings RANI|SNYR - Company Aggregate Debts|RLYB - Company Debts|lexariabioscience.com - Company Aggregate Debts|PULM (Pulmatrix Corporation) - Company Total Debt Obligations|Company Debts PTHL (Pheton Holdings Limited)|Company Cumulative Debt APM|Company Debts LYRA (Lyra Therapeutics)|Company Total Debt tnfpharma.com (TNFA)|YCBD: Company Aggregate Debts|Company Cumulative Debt PainReform Corp PRFX|Auris Medical (CYTO) - Company Aggregate Debts|LIPO - Company Aggregate Debt|OptiNose - Company Aggregate Debts|Pieris Pharmaceuticals Inc (PIRS) - Company Total Debt Obligations|Company Aggregate Debts PROC|Company Total Debt Petros Pharma|Company Aggregate Debts QLI|Company Aggregate Debts SLRN (acelyrin.com)|Company Debts TFF Pharmaceuticals, Inc. TFFP